Wafu
2021-11-29
Yeah
Moderna stock surged 8% in premarket trading<blockquote>Moderna股价在盘前交易中飙升8%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":600567497,"tweetId":"600567497","gmtCreate":1638176694634,"gmtModify":1638176744143,"author":{"id":3575505100092231,"idStr":"3575505100092231","authorId":3575505100092231,"authorIdStr":"3575505100092231","name":"Wafu","avatar":"https://static.tigerbbs.com/0fa81128865bb0701d14c8c5b8570921","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Yeah</p></body></html>","htmlText":"<html><head></head><body><p>Yeah</p></body></html>","text":"Yeah","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/600567497","repostId":1106015985,"repostType":4,"repost":{"id":"1106015985","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638176514,"share":"https://www.laohu8.com/m/news/1106015985?lang=zh_CN&edition=full","pubTime":"2021-11-29 17:01","market":"us","language":"en","title":"Moderna stock surged 8% in premarket trading<blockquote>Moderna股价在盘前交易中飙升8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106015985","media":"Tiger Newspress","summary":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be re","content":"<p>Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.</p><p><blockquote>Moderna股价在盘前交易中飙升8%，因为该公司表示，针对奥密克戎的新covid-19疫苗可能会在2022年初准备就绪。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p><p><blockquote>Moderna首席医疗官保罗·伯顿(Paul Burton)表示，他怀疑新的奥密克戎冠状病毒变种可能会躲避目前的疫苗，如果是这样，重新配制的疫苗可能会在新年伊始上市。</blockquote></p><p> \"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p><p><blockquote>伯顿周日（11月28日）在BBC的安德鲁·马尔节目中表示：“我们应该了解当前疫苗在未来几周内提供保护的能力。”</blockquote></p><p> \"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p><p><blockquote>“如果我们必须制造一种全新的疫苗，我认为要到2022年初才能真正大量上市，”他说。</blockquote></p><p> \"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p><p><blockquote>“mRNA疫苗Moderna平台的非凡之处在于我们可以非常快地行动，”他补充道。</blockquote></p><p> The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p><p><blockquote>在奥密克戎变种病毒的消息传开后，这家总部位于麻省剑桥的生物技术公司于上周四美国感恩节早些时候动员了“数百名”员工。</blockquote></p><p> Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p><p><blockquote>伯顿先生说，保护应该仍然存在，这取决于一个人多久前接种疫苗，目前最好的建议是接种一种当前的新冠肺炎疫苗。</blockquote></p><p> \"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p><p><blockquote>“如果人们持观望态度，而你还没有接种疫苗，那就接种疫苗，”他说。“这是一种看起来很危险的病毒，但我认为我们现在的医疗设备中有很多工具来对抗它。”</blockquote></p><p> The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p><p><blockquote>奥密克戎病毒株的出现导致各国急于限制来自南部非洲的旅行。</blockquote></p><p> Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.</p><p><blockquote>由于担心这可能会加剧北半球冬季Covid-19激增并破坏全球经济复苏，上周五全球市场掀起了一波避险浪潮，并在周日中东本周开盘时持续。</blockquote></p><p> Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p><p><blockquote>Moderna在周五的一份新闻稿中表示，它正在迅速测试目前针对奥密克戎变种的疫苗，并研究两种候选加强剂。</blockquote></p><p> \"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p><p><blockquote>该公司表示：“自2021年初以来，Moderna制定了一项全面的战略，以预测令人担忧的新变种。”“该公司已多次证明有能力在60至90天内将新候选药物推进临床测试。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock surged 8% in premarket trading<blockquote>Moderna股价在盘前交易中飙升8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock surged 8% in premarket trading<blockquote>Moderna股价在盘前交易中飙升8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 17:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.</p><p><blockquote>Moderna股价在盘前交易中飙升8%，因为该公司表示，针对奥密克戎的新covid-19疫苗可能会在2022年初准备就绪。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p><p><blockquote>Moderna首席医疗官保罗·伯顿(Paul Burton)表示，他怀疑新的奥密克戎冠状病毒变种可能会躲避目前的疫苗，如果是这样，重新配制的疫苗可能会在新年伊始上市。</blockquote></p><p> \"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p><p><blockquote>伯顿周日（11月28日）在BBC的安德鲁·马尔节目中表示：“我们应该了解当前疫苗在未来几周内提供保护的能力。”</blockquote></p><p> \"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p><p><blockquote>“如果我们必须制造一种全新的疫苗，我认为要到2022年初才能真正大量上市，”他说。</blockquote></p><p> \"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p><p><blockquote>“mRNA疫苗Moderna平台的非凡之处在于我们可以非常快地行动，”他补充道。</blockquote></p><p> The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p><p><blockquote>在奥密克戎变种病毒的消息传开后，这家总部位于麻省剑桥的生物技术公司于上周四美国感恩节早些时候动员了“数百名”员工。</blockquote></p><p> Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p><p><blockquote>伯顿先生说，保护应该仍然存在，这取决于一个人多久前接种疫苗，目前最好的建议是接种一种当前的新冠肺炎疫苗。</blockquote></p><p> \"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p><p><blockquote>“如果人们持观望态度，而你还没有接种疫苗，那就接种疫苗，”他说。“这是一种看起来很危险的病毒，但我认为我们现在的医疗设备中有很多工具来对抗它。”</blockquote></p><p> The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p><p><blockquote>奥密克戎病毒株的出现导致各国急于限制来自南部非洲的旅行。</blockquote></p><p> Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.</p><p><blockquote>由于担心这可能会加剧北半球冬季Covid-19激增并破坏全球经济复苏，上周五全球市场掀起了一波避险浪潮，并在周日中东本周开盘时持续。</blockquote></p><p> Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p><p><blockquote>Moderna在周五的一份新闻稿中表示，它正在迅速测试目前针对奥密克戎变种的疫苗，并研究两种候选加强剂。</blockquote></p><p> \"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p><p><blockquote>该公司表示：“自2021年初以来，Moderna制定了一项全面的战略，以预测令人担忧的新变种。”“该公司已多次证明有能力在60至90天内将新候选药物推进临床测试。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106015985","content_text":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.\n\nModerna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.\n\"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.\n\"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.\n\"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.\nThe Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.\nProtection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.\n\"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"\nThe emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.\nFears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.\nModerna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.\n\"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":737,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/600567497"}
精彩评论